Engflag
Advertisements

Codelac Broncho with thymus

Quick links to important sections

Codelac Broncho with thymus

Selected form

There is no image.

Advertisements
Advertisements

Method of action: Anti-Inflammatory, Expectorant, Mucolytic, Secretory

Treatment option: Bronchitis, Respiratory Tract Disease, Pneumonia, Chronic Obstructive Lung Disease

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Codelac Broncho with thymus

Property Description
Active Ingredients Ambroxol, Serpylii Extract Fluid, Sodium Glycyrrhizinate
Form Liquid oral preparation (elixir or syrup), sometimes tablets
Pharmacological Class Combined Mucolytic and Expectorant Agent
Common Use Facilitates clearance of viscous sputum
Origin Hybrid (Synthetic and Plant-derived)

What Type of Medicine is Codelac Broncho with Thymus?

Codelac Broncho with thymus is categorized pharmacologically as a Combined Mucolytic and Expectorant Agent, explicitly designed to aid in the clearance of respiratory secretions. The primary synthetic active component, Ambroxol, is a mucolytic. This multi-component pharmaceutical entity is typically prepared as a liquid oral preparation, such as an elixir or syrup, making it suitable for simple oral administration, though other dosage forms may also be available. Its core function is to restore the physiological clearance mechanisms of the respiratory tract.

Composition and Origin: Is Codelac Broncho a Natural or Hybrid Preparation?

The preparation features a Hybrid preparation status because it strategically combines a synthetic ingredient with two distinct phytocomponents derived from natural sources. The synthetic component is Ambroxol (INN), a derivative of bromhexine with established secretolytic properties. Ambroxol is described as thinning mucus and helping restore the normal function of cilia in the airways. This means the medicine supports the body’s natural clearance mechanisms by targeting both the mucus and the structures that move it.

The preparation also contains Serpylii Extract Fluid (derived from Thymus species, commonly wild thyme) and Sodium Glycyrrhizinate (a derivative from licorice root). Thyme extract is utilized as an expectorant, and thyme preparations have been used traditionally to relieve coughs associated with colds. This composition leverages synthetic action alongside the complementary properties of botanical substances.

General Purpose: How Does This Combination Help with Respiratory Function?

The general purpose of this combination is to manage conditions associated with the presence of viscous sputum by simultaneously addressing its texture and its removal, thus promoting effective airway drainage. The preparation achieves this by utilizing a combined secretolytic action from Ambroxol to thin the thick, tenacious bronchial secretions, and an expectorant effect from the phytocomponents to enhance the body’s natural mechanisms for expelling the mucus. This strategic dual approach is essential for facilitating a less strenuous and more productive cough, which is the overall benefit sought in managing impaired respiratory clearance during a typical episode of cough with sputum.

Regulatory References

  1. EMA Public Summary on Thyme Herbal Medicinal Product
Advertisements

What side effects are possible with Codelac Broncho with thymus?

Possible Side Effects and Safety Information

The safety profile for this medicine is established based on the documented regulatory data for its active components, primarily Ambroxol Hydrochloride. Adverse reactions are formally classified by frequency and the body system affected, as mandated by official government regulatory authorities.

Adverse Reaction Scope

The most frequently reported side effects are generally non-serious and affect the Gastrointestinal System. These commonly include nausea, dyspepsia (indigestion), oral or pharyngeal hypoaesthesia (numbness), and changed taste (dysgeusia). Vomiting, diarrhea, and dry mouth are also noted in the uncommon frequency category.

Serious Adverse Reactions

Official regulatory documents note a rare but serious risk of Severe Cutaneous Adverse Reactions (SCARs), including conditions like Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, and Erythema multiforme. Anaphylactic reactions (severe allergic reactions) and angioedema have also been reported, though their exact frequency is classified as not known.

Population-Specific Safety Considerations

Specific restrictions concerning patient populations are formally defined in the regulatory labeling:

  • Pregnancy and Lactation: Use is not recommended during the first trimester of pregnancy and while breast-feeding, as the active substance passes into breast milk.
  • Organ Impairment: Caution is formally required for patients with severe hepatic (liver) or renal (kidney) impairment, potentially necessitating dosage adjustment or extended intervals between doses.

Safety Restrictions

Administration must be immediately discontinued if any signs of a progressive skin rash or mucosal lesions appear. Caution is also advised in patients with a history of peptic ulceration and those with compromised airways motility (e.g., primary ciliary dyskinesia).

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose with Codelac Broncho with thymus is officially documented to present as an extension of known effects, primarily involving the gastrointestinal system. Documented manifestations include nausea, vomiting, diarrhea, and epigastric pain. Other acute presentations noted in regulatory labeling are short-term anxiety, excessive saliva secretion, and throat irritation.

The official prescribing information identifies more severe outcomes, including the observation of severe poisoning effects and signs of cardiovascular instability such as hypotension (low blood pressure). Due to the Glycyrrhizinate component, high exposure also carries a specific risk for Mineralocorticoid excess.

When to Seek Urgent Medical Help

If overdose is suspected, the regulatory mandate requires patients to seek immediate medical attention, consulting a doctor or proceeding to a hospital for assistance. This urgency is emphasized by the fact that no specific antidote is known for the medication.

Official Overdose Management

Management of overdose is directed toward symptomatic therapy and mandatory patient observation. Certain procedural interventions are conditional: gastric lavage may be considered only if a very high overdose has occurred and the ingestion was within the first two hours. Additionally, regulatory documents highlight that accumulation of active metabolites is expected in patients with severe renal insufficiency or serious hepatic impairment following an overdose.

Advertisements

Therapeutic Uses of Codelac Broncho with thymus

The combined components of Codelac Broncho with thymus are commonly used to help manage symptoms related to physical discomfort that may interfere with daily functioning, applied in contexts involving inflammatory or irritative processes. Agents like Ambroxol are generally applied in contexts where additional symptomatic support is needed in patients with short- or long-term diseases of the lungs or airways.

Symptom Management and Clinical Contexts

This therapeutic approach is relevant for easing symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms, such as acute bronchitis, chronic bronchopulmonary diseases, and acute respiratory illnesses. It helps manage symptoms related to impaired sputum clearance, often used when symptoms create noticeable physiological strain, particularly when symptoms are linked to organ-specific functional stress.

By supporting the management of an ineffective cough, the therapy assists with maintaining functional stability.

“The goal is to provide supportive relief when symptoms interfere with routine activities and general comfort.”

Quick Fact: Symptomatic Support for Difficult Expectoration

This support helps maintain a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load.

Regulatory References

  1. European Medicines Agency therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Codelac Broncho with thymus

Populations for whom use is allowed: Adults, adolescents (over 12 years old), and children 2 years and older are the approved populations for use.

Eligibility Status Population Group or Condition
Contraindicated Known hypersensitivity to Ambroxol or any other excipient.
Children under 2 years of age.
Patients with rare hereditary conditions (e.g., fructose intolerance, galactose intolerance).
Not Recommended Pregnancy (First Trimester).
Nursing Mothers (Ambroxol is excreted in breast milk).
Conditional Use (Use with Caution) Patients with a history of peptic or gastric ulceration.
Patients with severe renal impairment or serious hepatic impairment.
Patients with compromised airways motility or asthma.

Official regulatory documents classify use based on age, physiological status, and underlying comorbidity. The medicine is contraindicated for infants under two years and patients with hypersensitivity or certain metabolic disorders. Use is not recommended during the first trimester of pregnancy and while breastfeeding. In all other cases, the official label permits use, though specific cautions apply to those with ulcer history, severe kidney issues, or liver issues.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Statements

The interaction profile for Codelac Broncho with thymus, based on regulatory documentation, details risks associated with co-administration and pharmacokinetic alterations.

Classification Interacting Substance/Class Official Regulatory Description
Prohibited Combination Cough Suppressants (e.g., Codeine) Not recommended for co-administration; risk of cough reflex depression leading to excessive accumulation of secretions and potential airway obstruction.
Pharmacodynamic Risk Drugs Inducing Hypokalaemia (e.g., Thiazide Diuretics, Corticosteroids) Risk of aggravating electrolyte imbalance (hypokalaemia) due to the mineralocorticoid-like activity of the Sodium Glycyrrhizinate component.
Exposure Modification Antibiotics (e.g., Amoxicillin, Cefuroxime, Erythromycin, Doxycycline) Co-administration increases the concentration of these antibiotics in bronchopulmonary secretions and sputum.

No mandatory timing-based separation rules have been explicitly documented in the official labeling for this product. Clinically relevant unfavorable interactions have generally not been observed with other standard medications for treating bronchitis-related conditions.

Population-Specific Interaction Notes

The clearance of the active component Ambroxol is formally documented to be reduced by 20–40% in patients with severe hepatic impairment. Furthermore, the accumulation of Ambroxol metabolites is expected in patients with severe renal impairment. These factors may influence the clinical context for any co-administered substances that are also reliant on hepatic or renal elimination pathways.

Advertisements

Mechanism of Action

The pharmacological action of Codelac Broncho is multi-mechanistic, focused entirely on modulating key respiratory processes. The synthetic component, Ambroxol, operates via a secretolytic and secretomotor mechanism. It targets Type II pneumocytes, stimulating the synthesis and release of pulmonary surfactant while also depolymerizing the viscous acid mucopolysaccharide fibers in secretions. This action decreases secretion viscosity and activates the ciliated epithelium to accelerate mucociliary transport rate. The Sodium Glycyrrhizinate metabolite acts as an enzyme inhibitor, selectively suppressing 11-beta-HSD, which results in increased local activity of endogenous cortisol in respiratory tissues. This cascade modulates inflammation and mucosal fluid retention. Concurrently, the Thymus Serpyllum extract provides a spasmolytic action by exerting a direct relaxing effect on the bronchial smooth muscle. This modulation affects airway resistance, facilitating a lower resistance path for secretion clearance. The combined effects ensure comprehensive modulation of the physical and inflammatory components of airway obstruction.

Advertisements

Dosage and Administration Information

Codelac Broncho with thymus is supplied as a liquid oral preparation, and its administration must strictly follow the labeled instructions for its active components. The instructions below define the standardized procedure for use, focusing on the route, frequency, and dosage constraints.

Official Administration Protocol

Administration Domain Official Guideline
Route of Administration The medicine is taken orally as a solution or syrup.
Timing in Relation to Meals Doses should be administered after food to adhere to the prescribed conditions of use.
Course Duration Use should be short-term; continued administration for more than 4 to 5 days requires a medical consultation.

Dosage Schedule and Frequency

The dosage is standardized based on the Ambroxol Hydrochloride component. The liquid must be measured accurately using a designated device.

Population Group Typical Daily Schedule
Adults and Adolescents (>12 years) Initial dose is typically 90 mg/day (e.g., 30 mg TID), reducing to 60 mg/day (e.g., 30 mg BID) for maintenance.
Children (6 to 12 years) Dosing is significantly reduced, typically to 30–45 mg/day in two to three divided doses.

Procedural Constraint

Missed Dose Rule: If a scheduled dose is missed, a double dose should not be taken to compensate for the skipped amount. The medicine is generally not recommended for use in children under 2 years of age.

Advertisements

Recent Clinical Evidence

Research Focus: Initial and Primary Outcomes

Research examined the effects of the drug in relation to the body's inflammatory response, particularly in the context of respiratory conditions. Studies have explored whether this approach is associated with observed changes in patient outcomes, specifically for productive cough.

Research has investigated whether the drug may be associated with a rapid lessening of acute symptoms and a possible change in flare-up frequency for some study participants with acute bronchitis.

  • One clinical study involving children with acute bronchitis reported that the drug, a fixed combination containing ambroxol and Thymus serpyllum (wild thyme) extract, showed a decrease in the duration of harassing cough compared to a study group receiving only ambroxol.
  • Studies subsequently explored the drug’s profile in participants with persistent symptoms, particularly those who have not responded adequately to standard mucolytic therapies.

Research Focus: Secondary Endpoints and Quality of Life

Studies also evaluated whether the drug is associated with changes in inflammatory markers. Preclinical data, often using animal models, reported that the combination was associated with a reduction in measures of acute inflammation, potentially indicating a contribution from the thyme component.

The highest reported symptom improvement rates were observed when the drug was studied in an outpatient setting for productive cough. Research examined whether this combination is associated with an increased participant response rate, noting that positive changes in cough severity and character were observed in a high percentage of both adult and child study participants within 5 to 7 days.

Research Focus: Safety and Monitoring Profile

Long-term safety data were reviewed in several studies, which described the frequency of adverse events. Study findings described the frequency of adverse events and characterized the majority of reported side effects as minor and temporary in the observed populations.

Clinical trial protocols typically included monitoring for participants to observe for any potential changes. The evidence base for how this drug may interact with pre-existing liver conditions remains limited.

Key Studies & References

  1. Study to Investigate the anti-inflammatory effect of Codelac® Broncho with Thymus Serpyllum (elixir) in comparison with reference drug Fenspiride (syrup) using accute Carrageenan-induced Paw Inflammation Model
  2. RU2426531C1 - Liquid water pharmaceutical composition of ambroxol and pharmaceutical preparation based on it, intended for treating diseases of respiratory ways with formation of viscous sputum (versions) - Google Patents (Regulatory Context)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Codelac Broncho with thymus (FAQ)

Q: What is Codelac Broncho with thymus used for?

Codelac Broncho with thymus is a combination drug used to treat certain cough and respiratory conditions. It contains active ingredients that work to address symptoms like inflammation, sputum production, and irritation of the airways.

Q: What are the main ingredients in Codelac Broncho with thymus?

Codelac Broncho with thymus typically contains three main active components:

  • Ambroxol: A mucolytic agent that helps thin and loosen mucus/phlegm in the lungs, making it easier to cough up.
  • Sodium Glycyrrhizinate: Derived from licorice root, this ingredient is often included for its purported anti-inflammatory effects.
  • Thyme extract (or Thymus serpyllum extract): Used in traditional medicine as an expectorant to help relieve chest congestion and cough symptoms.

Q: How does Codelac Broncho with thymus relieve a cough?

The combination of ingredients provides relief through several mechanisms:

  1. Mucus Thinning (Ambroxol): Ambroxol acts as a mucolytic, breaking down the structure of thick mucus in the respiratory tract. This liquefies the sputum, making it less sticky and easier to clear from the airways.
  2. Expectorant Action (Thyme): Thyme extract helps stimulate the respiratory system, promoting the expulsion of mucus (expectoration).
  3. Anti-inflammatory Effects (Sodium Glycyrrhizinate): Sodium Glycyrrhizinate is included for its purported properties that may help reduce irritation and inflammation in the bronchial tubes.

Q: Is Codelac Broncho with thymus a cough suppressant?

No. Codelac Broncho with thymus is primarily formulated as an expectorant and mucolytic drug. Its main goal is to help you cough up mucus by thinning it and stimulating the cough reflex, rather than suppressing the cough itself.

Q: Can Codelac Broncho with thymus be taken with food?

Yes, Codelac Broncho with thymus is generally safe to take with or without food. Taking it with a meal may help reduce any potential stomach irritation.

Q: What should I do if I miss a dose of Codelac Broncho with thymus?

If you miss a dose, take it as soon as you remember. However, do not take the missed dose if it is almost time for your next scheduled dose. Never take two doses at once to make up for a missed dose.

Q: Are there any common side effects of Codelac Broncho with thymus?

As with most medications, some individuals may experience side effects. Common, typically mild, side effects can include:

  • Gastrointestinal upset (such as nausea or abdominal pain)
  • Allergic reactions (rash, itching)
  • Heartburn
  • Taste disturbance

If you experience any severe or persistent side effects, contact a healthcare professional immediately.

Q: Should I take Codelac Broncho with thymus if I have a history of peptic ulcers?

Patients with a history of peptic ulcers should use Codelac Broncho with thymus with caution. Ambroxol, one of the active ingredients, may have effects that could potentially irritate the stomach lining. It is essential to consult a healthcare professional before use to ensure the medication is safe for your specific condition.

Advertisements

How should Codelac Broncho with thymus be stored and disposed of?

How to Store and Dispose of Codelac Broncho with thymus

Storage and disposal instructions are strictly defined by regulatory labeling to maintain product integrity and ensure safety.

Storage and Stability Requirements

The medicine must be stored at a temperature no higher than 25^circC and kept out of the reach of children. To maintain chemical stability and protect the product from light, it must remain in its original container and outer cardboard packaging.

Once the bottle is first opened, the medicine has an in-use stability limit; any unused portion must be discarded 4 weeks after opening.

Official Disposal Instructions

Expired or unused portions of Codelac Broncho with thymus must not be disposed of by pouring into sewage or placing in household trash. Regulatory guidance mandates that the product be returned to a pharmacy or a designated collection point for appropriate pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Codelac Broncho with thymus found in:

A-Z Index: